Investors & Partners at OrbiMed Advisors

Carter Neild

Managing Partner, OrbiMed Advisors

Sven H. Borho is a founding partner at OrbiMed who heads the firm's public equity team and serves as portfolio manager for flagship listed healthcare strategies, including the London-listed Worldwide Healthcare Trust, giving him an unusual role that spans both specialist healthcare investing and public trust management. He emphasizes a science-first investment philosophy where understanding underlying biology and clinical science takes priority over financial metrics, distinguishing his approach from more traditional public equity managers.

David Bonita

General Partner, OrbiMed Advisors

Sven H. Borho is a founding partner at OrbiMed who heads the firm's public equity team and serves as portfolio manager for flagship listed healthcare strategies, including the London-listed Worldwide Healthcare Trust, giving him an unusual role that spans both specialist healthcare investing and public trust management. He emphasizes a science-first investment philosophy where understanding underlying biology and clinical science takes priority over financial metrics, distinguishing his approach from more traditional public equity managers.

Geoffrey C. Hsu

General Partner, OrbiMed Advisors

Sven H. Borho is a founding partner at OrbiMed who heads the firm's public equity team and serves as portfolio manager for flagship listed healthcare strategies, including the London-listed Worldwide Healthcare Trust, giving him an unusual role that spans both specialist healthcare investing and public trust management. He emphasizes a science-first investment philosophy where understanding underlying biology and clinical science takes priority over financial metrics, distinguishing his approach from more traditional public equity managers.

Matthew Rizzo

General Partner, OrbiMed Advisors

Sven H. Borho is a founding partner at OrbiMed who heads the firm's public equity team and serves as portfolio manager for flagship listed healthcare strategies, including the London-listed Worldwide Healthcare Trust, giving him an unusual role that spans both specialist healthcare investing and public trust management. He emphasizes a science-first investment philosophy where understanding underlying biology and clinical science takes priority over financial metrics, distinguishing his approach from more traditional public equity managers.

Peter Thompson

General Partner, OrbiMed Advisors

Sven H. Borho is a founding partner at OrbiMed who heads the firm's public equity team and serves as portfolio manager for flagship listed healthcare strategies, including the London-listed Worldwide Healthcare Trust, giving him an unusual role that spans both specialist healthcare investing and public trust management. He emphasizes a science-first investment philosophy where understanding underlying biology and clinical science takes priority over financial metrics, distinguishing his approach from more traditional public equity managers.

Scotland Stevens

General Partner, OrbiMed Advisors

Sven H. Borho is a founding partner at OrbiMed who heads the firm's public equity team and serves as portfolio manager for flagship listed healthcare strategies, including the London-listed Worldwide Healthcare Trust, giving him an unusual role that spans both specialist healthcare investing and public trust management. He emphasizes a science-first investment philosophy where understanding underlying biology and clinical science takes priority over financial metrics, distinguishing his approach from more traditional public equity managers.

Sven H. Borho

Managing Partner, OrbiMed Advisors

Sven H. Borho is a founding partner at OrbiMed who heads the firm's public equity team and serves as portfolio manager for flagship listed healthcare strategies, including the London-listed Worldwide Healthcare Trust, giving him an unusual role that spans both specialist healthcare investing and public trust management. He emphasizes a science-first investment philosophy where understanding underlying biology and clinical science takes priority over financial metrics, distinguishing his approach from more traditional public equity managers.